Axicabtagene Ciloleucel & Non-Hodgkin-Lymphoma

FDA status:

In the context of Axicabtagene Ciloleucel & Non-Hodgkin-Lymphoma, FDA initially approved October 2017 for adults with relapsed/refractory aggressive B‑cell non‑Hodgkin lymphoma after ≥2 lines of systemic therapy, including diffuse large B‑cell lymphoma (DLBCL) and related large B‑cell entities; later expanded to earlier‑line large B‑cell lymphoma and to follicular lymphoma based on ZUMA‑7 and ZUMA‑5 (1, 2, 3).

EMA status:

EMA authorized similarly for adult patients with relapsed/refractory DLBCL and other large B…